{"id":"control-group-oxiracetam-injection","safety":{"commonSideEffects":[{"rate":null,"effect":"Insomnia"},{"rate":null,"effect":"Nervousness or agitation"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Gastrointestinal disturbances"}]},"_chembl":{"chemblId":"CHEMBL4303394","moleculeType":"Small molecule","molecularWeight":"158.16"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Oxiracetam is a cyclic derivative of GABA that modulates neuronal membrane properties and increases cerebral blood flow and oxygen consumption. It enhances synaptic plasticity and neurotransmitter synthesis, particularly acetylcholine, supporting cognitive processes. The drug is believed to stabilize cell membranes and improve mitochondrial function in neurons.","oneSentence":"Oxiracetam enhances neuronal membrane fluidity and increases oxygen utilization in the brain, promoting cognitive function and neuroprotection.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:45:21.158Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Cognitive decline and memory impairment"},{"name":"Stroke recovery and post-stroke cognitive dysfunction"},{"name":"Age-related cognitive disorders"}]},"trialDetails":[{"nctId":"NCT04205565","phase":"PHASE3","title":"Study on Clinical Effectiveness of L-Oxiracetam Injection","status":"UNKNOWN","sponsor":"Nanjing Yoko Biomedical Co., Ltd.","startDate":"2019-09-30","conditions":"Craniocerebral Injury","enrollment":591}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Control group: Oxiracetam Injection","genericName":"Control group: Oxiracetam Injection","companyName":"Nanjing Yoko Biomedical Co., Ltd.","companyId":"nanjing-yoko-biomedical-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Oxiracetam enhances neuronal membrane fluidity and increases oxygen utilization in the brain, promoting cognitive function and neuroprotection. Used for Cognitive decline and memory impairment, Stroke recovery and post-stroke cognitive dysfunction, Age-related cognitive disorders.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}